Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis
Recruiting in Palo Alto (17 mi)
+45 other locations
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Eli Lilly and Company
Prior Safety Data
Trial Summary
What is the purpose of this trial?This study is being done to test the safety and efficacy of LY3556050 for the treatment of osteoarthritis pain. This trial is part of the chronic pain master protocol, H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.
Eligibility Criteria
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3556050 600 mgExperimental Treatment1 Intervention
Participants received 600 mg LY3556050 twice daily (BID) every 12 hours for up to 8 weeks.
Group II: PlaceboPlacebo Group1 Intervention
Participants received placebo BID every 12 hours for up to 8 weeks.
Find A Clinic Near You
Research locations nearbySelect from list below to view details:
Clinical Research Center of Reading,LLCWyomissing, PA
Northwest Clinical Research CenterBellevue, WA
Synexus - San AntonioSan Antonio, TX
Altoona Center For Clinical ResearchDuncansville, PA
More Trial Locations
Loading ...
Who is running the clinical trial?
Eli Lilly and CompanyLead Sponsor